BofA Securities reiterates Buy rating on Definitive Healthcare stock

Definitive Healthcare Corp (NASDAQ:DH) reported robust second-quarter 2025 results, exceeding both BofA Securities' and consensus estimates for revenue and EBITDA, while also raising its full-year 2025 revenue guidance. The company posted an EPS of $0.07 on revenue of $60.8 million, showcasing an impressive 83.4% gross profit margin and notable improvements in renewal and retention rates. Following this strong performance, BofA Securities reiterated its Buy rating and $4.50 price target, based on 10.0x CY26E EBITDA, acknowledging the company's operational efficiency and strategic progress despite anticipating continued near-term macroeconomic pressures.

Analysis

Definitive Healthcare Corp (DH) delivered a robust second quarter for 2025, with revenue of $60.8 million and EPS of $0.07 both surpassing consensus estimates. The performance was underpinned by strong operational efficiency, evidenced by an impressive gross profit margin of 83.4%. Following the results, the company raised its full-year 2025 revenue guidance by $1.5 million at the midpoint, an increase that almost entirely reflects the $1.6 million beat from the second quarter, suggesting a stable outlook for the remainder of the year rather than an acceleration. Critically, the company is showing early signs of a successful operational pivot, with modest improvements in renewal rates and its highest client retention rate since Q2 2024. BofA Securities has reiterated its Buy rating and a $4.50 price target, although this target is now based on a more conservative 10.0x CY26E EBITDA multiple, rolled forward from a previous 11.5x CY25E EBITDA. This valuation adjustment likely reflects BofA's expectation of continued macroeconomic headwinds through 2025 and into 2026, which tempers the otherwise positive company-specific developments.

Key Decisions for Investors

• Given the strong Q2 2025 earnings beat, improved retention rates, and reaffirmed analyst price target, investors may consider the results as validation of the company's operational turnaround.
• It is critical to note that the full-year guidance hike was almost entirely due to the Q2 outperformance, and BofA's valuation multiple has been compressed, suggesting a more conservative outlook for underlying growth amid persistent macroeconomic pressures.
• Closely monitor client renewal and retention rates in subsequent quarters, as sustained improvement in these metrics will be the key indicator that the firm's strategic initiatives are generating durable growth.
• Investors should weigh the company's positive internal momentum against the noted risk of a challenging macro environment, which analysts expect to persist through 2025 and into 2026.